Sotheby’s is a global art business company. The company has market cap of $2.62 billion. The Firm is engaged in offering its clients opportunities to connect with and transact in a range of objects. It has a 36.28 P/E ratio. The Firm offers a range of art-related services, including the brokerage of private art sales, private jewelry sales through Sotheby’s Diamonds, private selling exhibitions at its galleries, art-related financing, and art advisory services, as well as retail wine locations in New York and Hong Kong.
Analysts expect Flex Pharma Inc (NASDAQ:FLKS) to report $-0.63 EPS on May, 3.They anticipate $0.02 EPS change or 3.28% from last quarter’s $-0.61 EPS. After having $-0.48 EPS previously, Flex Pharma Inc’s analysts see 31.25% EPS growth. It is down 74.07% since September 16, 2016 and is downtrending. It has underperformed by 85.05% the S&P500.
Flex Pharma, Inc. is a biotechnology company. The company has market cap of $54.63 million. The Firm develops treatments for nocturnal leg cramps, muscle cramps and spasms associated with severe neuromuscular conditions, and exercise associated muscle cramps . It currently has negative earnings. The Company’s product candidates activate certain receptors in primary sensory neurons, which then act through neuronal circuits to reduce the repetitive firing, or hyperexcitability, of alpha-motor neurons in the spinal cord, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms.
Among 2 analysts covering Flex Pharma (NASDAQ:FLKS), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Flex Pharma had 3 analyst reports since August 21, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, August 21 by Zacks. Cantor Fitzgerald downgraded the shares of FLKS in report on Friday, October 14 to “Hold” rating. The firm earned “Hold” rating on Wednesday, September 2 by Zacks.
Since January 1, 0001, it had 3 buys, and 1 insider sale for $1.24 million activity.
About 425,361 shares traded. Sothebys (NYSE:BID) has risen 25.39% since September 16, 2016 and is uptrending. It has outperformed by 14.40% the S&P500.
Analysts await Sothebys (NYSE:BID) to report earnings on May, 8. They expect $-0.39 earnings per share, down 11.43% or $0.04 from last year’s $-0.35 per share. After $1.35 actual earnings per share reported by Sothebys for the previous quarter, Wall Street now forecasts -128.89% negative EPS growth.
